Alto Neuroscience (NYSE:ANRO) Sees Unusually-High Trading Volume – Still a Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) saw an uptick in trading volume on Monday . 303,331 shares traded hands during trading, a decline of 19% from the previous session’s volume of 373,522 shares.The stock last traded at $34.9690 and had previously closed at $34.28.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. Wall Street Zen upgraded Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Robert W. Baird decreased their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. BTIG Research lifted their target price on Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Finally, Bank of America started coverage on Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.25.

Alto Neuroscience Price Performance

The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The firm has a market cap of $1.42 billion, a PE ratio of -14.96 and a beta of 1.06. The firm’s fifty day simple moving average is $27.97 and its two-hundred day simple moving average is $23.74.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08. As a group, research analysts expect that Alto Neuroscience, Inc. will post -2.68 EPS for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in shares of Alto Neuroscience in the first quarter worth about $52,000. Torren Management LLC bought a new position in Alto Neuroscience in the 4th quarter worth approximately $62,000. Invesco Ltd. purchased a new stake in Alto Neuroscience during the 1st quarter valued at approximately $67,000. Bridgeway Capital Management LLC grew its holdings in Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after buying an additional 25,000 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Alto Neuroscience during the fourth quarter valued at approximately $198,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.